Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using MEK-2(Phospho-Thr394) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MEK-2(Phospho-Thr394) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HepG2 and Hela cells untreated or treated with UV using MEK-2(Phospho-Thr394) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using G3BP-1(Phospho-Ser232) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using G3BP-1(Phospho-Ser232) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with starvation using G3BP-1(Phospho-Ser232) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Pyk2(Phospho-Tyr402) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Pyk2(Phospho-Tyr402) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with Serum using Pyk2(Phospho-Tyr402) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin- embedded human breast carcinoma tissue using Src (phospho- Tyr418) antibody.)
WB (Western Blot) (Western blot analysis of extracts from COLO205 cells using Src (Ab-418) antibody (Lane 1 and 2) and Src (phospho-Tyr418) antibody (Lane 3 and 4).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Synaptotagmin (phospho-Thr202) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from colo cells (Lane 2), using Synaptotagmin (Phospho-Thr202) Antibody. The lane on the left is treated with antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using Estrogen Receptor-alpha (Phospho-Tyr537) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from K562 cells (Lane 2), using Estrogen Receptor-alpha (Phospho-Tyr537) Antibody. The lane on the left is treated with antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human brain tissue using FRS2 (Phospho-Tyr436) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from HuvEc cells (Lane 2) and JK cells (Lane 3), using FRS2 (Phospho-Tyr436) Antibody. The lane on the left is treated with antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Gab2 (Phospho-Ser623) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells (Lane 2), HeLa cells (Lane 3) and HepG2 cells (Lane 4), using Gab2 (Phospho-Ser623) Antibody. The lane on the left is treated with antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using ABL1/2(phospho-Tyr393/439) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ABL1/2(Phospho-Tyr393/439) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HL60 cells using ABL1/2(phospho-Tyr393/439) Antibody and the same antibody preincubated with blocking peptide.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from COS7 cells, treated with UV or calf intestinal phosphatase (CIP), using ATF2 (Phospho-Thr73 or 55) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using ATF2(Phospho-Thr73 or 55) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ATF2(Phospho-Thr73 or 55) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells untreated or treated with EGF using ATF2(Phospho-Thr71 or 53) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MEF cells untreated or treated with LY2904 using FKHR (Phospho-Ser256) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF7 cells using FKHR(Phospho-Ser256) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using FKHR (Phospho-Ser256) Antibody (left) or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with serum using FKHR(Phospho-Ser256) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with Noc or calf intestinal phosphatase (CIP), using NF-kappa;B-p105/p50(Phospho-Ser337) Antibody.)
WB (Western Blot) (Western blot analysis of extract from HeLa cells, using NF-kappa;B p105/p50 (phospho-Ser337) antibody (Lane 1 and 2).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin- embedded human breast carcinoma tissue using NF-kappa;B p105/p50 (phospho-Ser337) antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed HeLa cells using NF-kappa;B p105/p50 (phospho-Ser337) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human Lung carcinoma tissue using NFkappaB-p65 (Phospho-Ser536) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFkappaB-p65 (Phospho-Ser536) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using NFkB-p65(Phospho-Ser536) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFkappaB-p65 (Phospho-Ser536) Antibody (left) or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from HepG2 and HL60 cells untreated or treated with TNF using NFkB-p65(Phospho-Ser536) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with IFNa or calf intestinal phosphatase (CIP), using STAT1 (Phospho-Tyr701) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from MEF cells untreated or treated with interferon-96)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with PMA or calf intestinal phosphatase (CIP), using p90RSK (Phospho-Ser352) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from HUVEC cells using p90RSK(Phospho-Ser352) Antibody(Lane 2) and the same antibody preincubated with blocking peptide(Lane1).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using b-Catenin(Phospho-Ser37) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HT29 cells using b-Catenin(Phospho-Ser37) Antibody and the same antibody preincubated with blocking peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using S6 Ribosomal Protein(Phospho-Ser235) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from PC12 cells untreated or treated with anisomycin using S6 Ribosomal Protein(Phospho-Ser235) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using a-Synuclein(Phospho-Tyr133) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from C2C12 cells untreated or treated with Anisomycin using a-Synuclein(Phospho-Tyr133) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with starve or calf intestinal phosphatase (CIP), using SHP-2 (Phospho-Tyr580) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using SHP-2(Phospho-Tyr580) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
DB (Dot Blot) (Dot blot analysis of Phospho-ERBB2-Y877 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from T47D cells, untreated or treated with NRG, 100ng/ml, using phospho-ErBB2(Y877) (left) or ErBB2 antibody(right).)
IF (Immunofluorescence) (Immunofluorescent analysis of Rabphilin 3A (phospho-hospho-Ser237) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with Alexa Fluor 647-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Rabphilin 3A (phospho-Ser237) staining in human brain formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Rabphilin 3A (phospho-Ser237) expression in Raw264.7 Calyculin treated whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of TYRO3/MERTK (phospho-Tyr749/681) staining in human brain formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of TYRO3/MERTK (phospho-Tyr749/681) expression in HEK293T, H1688, NIH3T3 EGF-treated whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of Ezrin/Radixin/Moesin (phospho-Thr567/564/558) staining in SKOV3 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Ezrin/Radixin/Moesin (phospho-Thr567/564/558) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Ezrin/Radixin/Moesin (phospho-Thr567/564/558) expression in SKOV3, NIH3T3 whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of NEK9 (phospho-Thr210) staining in THP1 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of NEK9 (phospho-Thr210) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of NEK9 (phospho-Thr210) expression in THP1, HepG2, Hela whole cell lysates.)
Application Data (Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast carcinoma tissue showing cytoplasmic staining.)
WB (Western Blot) (Western blot analysis of eIF2alpha phosphorylation in untreated (A, C) and lambda protein phosphatase treated (B, D) HEK293 whole cell lysates. Antibodies tested include p-eIF2alpha (Ser 52) (A, B) and eIF2alpha (C, D).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-Phospho-PKR (T446) antibody. Counter stained with hematoxylin.)
WB (Western Blot) (Western blot analysis of Phospho-PKR (T446) on different lysates using anti-Phospho-PKR (T446) antibody at 1/1, 000 dilution. Positive control: Lane 1: Hela treated with Calyculin A and TNF-alpha whole cell lysates Lane 2: Untreated Hela whole cell lysates)
ICC (Immunocytochemistry) (ICC staining phospho-FAK (Y397) in NIH/3T3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining phospho-FAK (Y397) in N2A cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining phospho-FAK (Y397) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded mouse colon tissue using anti-Phospho-STAT1 (S727) antibody. Counter stained with hematoxylin.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-Phospho-STAT1 (S727) antibody. Counter stained with hematoxylin.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using anti-Phospho-STAT1 (S727) antibody. Counter stained with hematoxylin.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded rat skeletal muscle tissue using anti-Phospho-Raf1 (S259) antibody. Counter stained with hematoxylin.)
WB (Western Blot) (Western blot analysis of Phospho-Raf1 (S259) on different lysates using anti-Phospho-Raf1 (S259) antibody at 1/1, 000 dilution. Positive control: Lane 1: Human skeletal muscle Lane 2: Hela)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using Cyclin E1 (phospho-Thr395) antibody)
WB (Western Blot) (Western blot analysis of extracts from HeLa cells, treated with Paclitasel (1uM, 60mins), using Cyclin E1 (phospho-Thr395) antibody.)
WB (Western Blot) (Western blot analysis of lysates from A431 cell line, untreated or treated with EGF, 100ng/ml, using Phospho-HUMAN-ARHGAP35(Y1105) (upper) or Beta-actin (lower).)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-Rb-S780 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (The anti-Phospho-Bad-S75 Pab is used in Western blot to detect Phospho-Bad-S75 in HL60 tissue lysate)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-Nanog-S71 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IF (Immunofluorescence) (Fluorescent confocal image of SY5Y cells stained with AAA288713 Phospho-Nanog-S71 antibody. SY5Y cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min), then incubated with AAA288713 Phospho-Nanog-S71 primary antibody (1:500, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Cytoplasmic actin was counterstained with Alexa Fluor 555 (red) conjugated Phalloidin (5.25 uM, 25 min). Phospho-Nanog immunoreactivity is localized very specifically to the nuclei of the SY5Y cells.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (Western blot analysis of anti-Phospho-Caspase-pS257 in liver cell line lysates (35ug/lane). Casp6-pS257(arrow) was detected using the purified Pab.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (The anti-Phospho-GSK3B-S21/29 Pab is used in Western blot to detect Phospho-GSK3B-S21/29 in mouse thymus tissue lysate.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using VE-Cadherin (Phospho-Tyr731) antibody.)
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells, treated with Na3VO4 (0.3mM, 40mins), using VE-Cadherin (Phospho-Tyr731) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun(Phospho-Thr91) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with UV using c-Jun(Phospho-Thr91) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells, treated with serum or calf intestinal phosphatase (CIP), using MARCKS (phospho-Ser170) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using MARCKS(Phospho-Ser170) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from MCF cells untreated or treated with EGF using MARCKS(phospho-Ser170) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using PAK1(Phospho-Thr212) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using PAK1(Phospho-Thr212) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with forskolin using PAK1(Phospho-Thr212) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human heart tissue using PEA-15 (Phospho-Ser104) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from COS cells treated with TNF using PEA-15 (Phospho-Ser104) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with UV+serum or calf intestinal phosphatase (CIP), using Histone H2A.X (Phospho-Ser139) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Histone H2A.X(Phospho-Ser139) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from HT29 cells untreated(lane 1) or treated with UV(lane 2) using Histone H2A.X(Phospho-Ser139) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with PMA or calf intestinal phosphatase (CIP), using p90RSK (Phospho-Ser352) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from HUVEC cells using p90RSK(Phospho-Ser352) Antibody (Lane 2) and the same antibody preincubated with blocking peptide(Lane1).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue, using BIK (Phospho-Thr33) antibody (#A0053). The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from K562 cells, using BIK (Phospho-Thr33) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed HeLa cells using Chk2 (Phospho-Thr383) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from COS7 cells treated with UV using Chk2 (Phospho-Thr383) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.